Efficacy and Safety of Peficitinib for Treating Rheumatoid Arthritis :A Systematic Review
- VernacularTitle:Peficitinib治疗类风湿关节炎疗效和安全性的系统评价
- Author:
Xin LIU
1
;
Changjing XU
1
,
2
;
Xiaoyan ZHONG
2
;
Danjie ZHAO
1
;
Bin YU
3
;
Yilan HUANG
2
Author Information
1. School of Pharmacy,Southwest Medical University,Sichuan Luzhou 646000,China
2. Dept. of Pharmacy,the Affiliated Hospital of Southwest Medical University,Sichuan Luzhou 646000,China
3. Dept. of Pharmacy,Mianyang Central Hospital,Sichuan Mianyang 621000,China
- Publication Type:Journal Article
- Keywords:
Peficitinib;
Rheumatoid arthritis;
JAK inhibitor;
Meta-analysis
- From:
China Pharmacy
2020;31(7):859-864
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically evaluate the efficacy and safety of pe ficitinib for treating rheumatoid arthritis (RA),and to provide evidence-based reference for the clinical treatment of RA. METHODS :Retrieved from PubMed ,Embase, The Cochrane Library ,CJFD,VIP and Wanfang database during from their establishment to September 2019,randomized controlled trials (RCTs)about the efficacy and safety of Peficitinib (trial group )versus placebo (control group )in the treatment of RA were collected. The risk of bias assessment tool provided in Cochrane System Evaluator Manual 5.1.0 was used to evaluate the quality after data extracted from clinical studies which met the inclusion criteria. Meta-analysis of the efficacy [the proportion of patients who met the American College of Rheumatology 20% improvement criteria (ACR20),ACR50,ACR70,the proportion of the patients with 28 joint disease activity index <2.6 calculated by erythrocyte sedimentation rate (DAS28-ESR<2.6),the proportion of patients with 28 joint disease activity index <2.6 calculated by C-reactive protein (DAS28-CRP<2.6),etc.] and safety(incidence of total ADR )was performed by using Stata 16 statistical software. RESULTS :Totally 5 RCTs were included , 药学。E-mail:hyl3160131@163.com 5.11),P<0.001],150 mg[RR=3.52,95%CI(1.78,6.96),P< 0.001]},ACR70{total [RR =2.51,95%CI(1.52,4.14),P<0.001],100 mg[RR=3.50,95%CI(1.62,7.58),P=0.001],150 mg [RR=4.59,95%CI(1.47,14.30),P=0.009]},DAS28-ESR<2.6{total [RR =4.83,95%CI(3.20,7.28),P<0.001],100 mg[RR= 5.37,95%CI(2.68,10.77),P<0.001],150 mg[RR=7.44,95%CI(3.78,14.65),P<0.001]} and DAS 28-CRP<2.6{total [RR =3.41, 95%CI(2.65,4.39),P<0.001],100 mg[RR=4.00,95%CI(2.67,5.99),P<0.001],150 mg[RR=4.45,95%CI(2.99,6.63),P< 0.001]} in trial group were significantly higher than control group ,with statistical significance. In term of safety ,there was no statistical significance in the incidence of total ADR [RR =1.05,95% CI(0.94,1.16),P=0.395] between 2 groups. CONCLUSIONS:For the treatment of RA ,100 mg or 150 mg peficitinib once per day is superior to placebo in terms of ACR 20, ACR50 and ACR 70,DAS28-ESR<2.6,DAS28-CRP<2.6; the adverse events are mild and tolerable and it may be a new treatment option for RA.